mk-3118 and Vulvovaginitis

mk-3118 has been researched along with Vulvovaginitis* in 1 studies

Other Studies

1 other study(ies) available for mk-3118 and Vulvovaginitis

Article	Year
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5 Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and Topics: Animals; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Drug Resistance, Fungal; Female; Glycosides; Hydrogen-Ion Concentration; Mice; Microbial Sensitivity Tests; Triterpenes; Vulvovaginitis	2019

Article

Year

A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.

Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5

Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and

Topics: Animals; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Drug Resistance, Fungal; Female; Glycosides; Hydrogen-Ion Concentration; Mice; Microbial Sensitivity Tests; Triterpenes; Vulvovaginitis

2019